Health Care & Life Sciences » Biotechnology | Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc. | Ownership

Companies that own Five Prime Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
5,281,363
14.84%
52,319
0.01%
06/30/2018
Wellington Management Co. LLP
4,319,970
12.14%
-219,376
0.01%
06/30/2018
BlackRock Fund Advisors
2,594,815
7.29%
202,736
0%
06/30/2018
BVF Partners LP
2,155,324
6.06%
1,025,563
2.02%
09/04/2018
The Vanguard Group, Inc.
2,153,428
6.05%
72,065
0%
06/30/2018
SSgA Funds Management, Inc.
1,906,183
5.36%
-118,402
0%
06/30/2018
Great Point Partners LLC
1,260,000
3.54%
391,900
2.42%
06/30/2018
Dimensional Fund Advisors LP
1,189,654
3.34%
147,904
0%
06/30/2018
Victory Capital Management, Inc.
1,102,760
3.1%
35,670
0.03%
06/30/2018
T. Rowe Price Associates, Inc.
1,037,941
2.92%
-96,124
0%
06/30/2018

About Five Prime Therapeutics

View Profile
Address
111 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.fiveprime.com
Updated 07/08/2019
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.